• Inicio
• Patronato
• Comité Internacional
• Congresos
• Publicaciones
• Investigación y Docencia
• Contactar

Congresos

International Meeting on Dopamine Disease States

Mojácar (Almería)

October 18 - 22 1995

The content of this congress, together with other contributions on the topic, are collected in vol. 3 of the series "Strategies for studying brain disorders". (The book is also available in Spanish).

PROGRAMME

• Tomás Palomo, Spain.
  Opening Remarks.
• Erik Clavería, Spain.
  Neuroscience research in Spain and in collaboration with other countries.

S1. DOPAMINE-SCHIZOPHRENIA

• Sven-Ove Ögren, Sweden.
  The pharmacological profiles of new and awaited anti-psychotic agents.
• William Deakin, UK.
  Preclinical and clinical evidence for the excitatory amino-acids in schizophrenia.
• Bita Moghaddam, USA.
  Dopamine-glutamate interactions and Cognitive Deficits.
• Jeffrey M. Goldstein, USA.
  Pre-clinical tests that predict Clozapine-like atypical antipsychotic actions.
• S2. DOPAMINE-PARKINSON'S DISEASE.
• Jogren Scheel-Krüger, Denmark.
  Antagonism and reversal of the MPTP biochemical and behavioural effects in rodents and marmosets by NS 2214, a novel dopamine uptake inhibitor.
• Trevor Archer, Sweden.
  Dopaminergic-glutamatergic balance in the forebrain: functional studies of movement disorders in rats and mice
• Juan José López-Lozano, Spain.
  Experience with implantation of fetal mesencephalon in Parkinson's Disease: clinical results in 10 grade IV-V patients.
• Alberto Portera-Sánchez, Spain.
  Epidemiology, etiology and clinical perspectives of parkisonisms.

S3. DOPAMINE-ADDICTION AND NEUROCHEMISTRY

• Lew Seiden, USA.
  Methamphetamine (MA) engendered neurotoxicity to dopamine (DA) neurons: mechanism of action.
• Javier Fernández-Ruiz, Spain.
  Dopaminergic neurons as neurochemical substrates of neurobehavioral effects of marihuana: developmental and adult studies.
• Miguel Casas-Brugé, Spain.
  Relevance of dopamine systems in chemical addictions.
• Peter Kalivas, USA.
  Preclinical-clinical aspects of drug-and stress-induced psychosis.

S4. DOPAMINE DISORDER INTERACTIVE STUDIES

• David Jackson, Sweden.
  Clozapine: New biochemical and behavioural studies on its mechanism of action.
• Jorge Manzanares, Spain.
  Kappa opioid receptor regulation of nigrostriatal, mesolimbic, tuberoinfundibular and periventricular-hypophysial dopaminergic neurons in the male rat.
• Richard J. Beninger, Canada.
  Dopamine D1-like receptors and molecular mechanisms of incentive learning.
• Johan Luthman, Sweden.
  Functional and neurochemical responses to interventions in the developing dopamine system.
• Rik Broekkamp, The Netherlands.
  Role of dopamine-serotonin interrelationships in psychotropic drug effects.

S5. DOPAMINE-GENERAL CONSIDERATIONS

• Pierre Sokoloff, France.
  Multiple dopamine receptors: their significance for disease states.
• Bart Ellenbroek, The Netherlands.
  Dopamine and information processing.
• Klaus Ebmeier, UK.
  Imaging functional change and dopaminergic activity in depression.
• Ivan Izquierdo, Brasil.
  Synaptic mechanism in hippocampus, amygdala and enthorhinal cortex involved in memory formation, storage and expression.

S6. DOPAMINE DISEASE STATES

• Nancy Andreasen, USA.
  Neural substrates of frontal lobe function.
• Robin Murray, UK.
  Dementia praecox or developmental insanity: a new perspective on an old debate.
• George Koob, USA.
  Dopamine subtype receptor profiles in reward and abuse.
• Tim Crow, UK.
  The failure of the dopamine hypothesis and its consequences for the future direction of psychosis research.

STRATEGIES FOR STUDYING BRAIN DISORDERS

Inscrita en el registro de fundaciones docentes y de investigación, MAD-1-3-601

© 2009 Fundación Cerebro y Mente Todos los derechos reservados